Pharma's Market
SPECIAL REPORT
MOST SHARED
- With Investors So Bullish, Pullback Must Be Coming
- How to Date a Wall Street Man
- LinkedIn CEO Calms Post-Lockup Concerns
- Why Greece Will Default, Leave the Euro Zone
- Stocks Hold Losses, Italian Banks Downgraded
- Blue Ivy Gets Trademarked By Beyonce And Jay-Z
- Get Ready for $5 Gas This Year: Ex-Shell CEO
- The World's Best Beers
- Housing Still Hurting Consumers, Economy: Bernanke
- Investing in the Fountain of Youth
- Private Homebuilders: Dead Men Walking
- LinkedIn’s Growth Is Already Priced In: Analyst
- The Real Reason Behind Bank of America’s Rally
- 5 Hedge Funds’ Top Stocks Soar After 2011 Rout
- This Valentine’s Day Love Is Served on a Silver Platter
- CEO to CEO: Our Roles Are Changing
- Clint Eastwood ‘Surprised’ by Reaction to Chrysler's ‘Halftime in America’ Ad
- Bulls Check In to Community Health
- Bank of America’s Worst-Case Scenario Gets More Real
- Is Bill Gross, PIMCO's Bond King, Losing His Touch?
- Greece Austerity Deal Runs Into Trouble Once Again
- Why Greece Will Default, Leave Euro Zone
- Apple’s Record Run: $500 Is a Magic Number
- Private Homebuilders: Dead Men Walking
- Housing Still Hurting Consumers, Economy: Bernanke
- Get Ready for $5 Gas This Year: Ex-Shell CEO
- The World's Best Beers
- Diamond Investing: Why It's Not for the Faint of Heart
RSS FEED
Getting to the Heart of the Merck-Abbott Embargo Break
CNBC Correspondent
Live TV is best when things are happening and news is breaking right now. It's immediate and often, hopefully, more compelling.
That's why I and the "Squawk Box" producers were happy with the American Heart Association's plan to lift the news media embargo on the Abbott [ABT
Loading...
()
] versus Merck [MRK
Loading...
()
] study at 8 a.m. ET this morning. That'd be right in the middle of their show. Breaking and potentially stock-moving news about huge drugs made by a Dow component. It had all the elements, including controversy about the results.
But it wasn't to be. Sometime Sunday afternoon a major wire service transmitted its embargoed story on the Zetia versus Niaspan study results. It was sent with the usual notation that the piece is under embargo until a certain date and time.
But apparently someone at a relatively small, local midwestern TV station didn't see the admonishment and posted the wire story on its Web site.
After catching or being told about the error, the station took it down almost immediately. But it was too late. "Google Alerts" grabbed it and so did other Web sites. The info was out there for everyone to see. The embargo had been inadvertently broken.
After a meeting of the minds between AHA, "The New England Journal of Medicine," and the two companies involved, it was decided that the embargo would be lifted for everyone else at 6 p.m. ET Sunday.
Reporters for other wire services and media outlets suddenly had to scramble to get their finished stories out a good 14 hours sooner than planned. And with data as important and sensitive as these, that kind of rush job isn't necessarily a good thing.
The upside, perhaps, is that it gave Wall Street analysts several hours to digest and comment on the results for their investor clients, rather than the hour-and-a-half they would've had before the opening bell if the embargo lifted at 8.
This isn't the first time an embargo has been broken and it won't be the last. If the circumstances were different, the AHA and NEJM would likely put the reporter or news outlet that broke it in the naughty corner.
This appears to be an honest mistake.
But it could have been and should have been avoided. I ain't perfect and there but for the grace of God go I, but I don't understand why a major wire service pushed out a story around 18 hours before an embargo lifted. It opens wide the door for an embargo break.
There's no reason that I can see to justify copy going out so early, especially in today's push-button news transmission world.
It needs to stop.
Questions? Comments? and follow me on Twitter at mhuckman








